

# Angina Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/ADB31448A30DEN.html>

Date: May 2024

Pages: 137

Price: US\$ 6,499.00 (Single User License)

ID: ADB31448A30DEN

## Abstracts

The 7 major angina markets reached a value of US\$ 6.8 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US\$ 10.1 Billion by 2034, exhibiting a growth rate (CAGR) of 3.7% during 2024-2034.

The angina market has been comprehensively analyzed in IMARC's new report titled "Angina Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Angina refers to a medical condition characterized by chest pain that develops when the heart muscle doesn't receive enough blood flow and oxygen. The pain is usually described as a squeezing, pressure, heaviness, tightness, or burning sensation in the chest, but it can also be felt in the arms, neck, jaw, shoulder, back, or stomach. Various other symptoms may include shortness of breath, sweating, nausea, dizziness, fatigue, etc. The pain or discomfort is triggered by physical activity, emotional stress, exposure to cold weather, or after a heavy meal, and tends to go away with rest. Diagnosing angina usually involves a medical history and physical examination to evaluate symptoms, risk factors, and a family history of heart disease. An electrocardiogram (ECG) is often performed to measure the electrical activity of the heart and look for any abnormalities. Numerous other procedures include a stress test to monitor the heart's response to physical activity, an echocardiogram to visualize the heart's structure and function, as well as blood tests to check for elevated levels of certain proteins or enzymes that indicate heart damage. Additionally, a coronary angiogram is also performed to view the coronary arteries and detect any blockages or narrowing that may be causing the angina symptoms.

The rising cases of coronary artery diseases, in which the arteries supplying blood to the heart muscle are blocked or narrowed due to the buildup of plaque, are primarily driving the angina market. In addition to this, the increasing prevalence of various risk

factors, such as coronary artery spasm, aortic valve stenosis, hypertrophic cardiomyopathy, arrhythmias, anemia, emotional stress, etc., is also bolstering the market growth. Moreover, the widespread adoption of several medications, including nitroglycerin, beta-blockers, calcium channel blockers, etc., for reducing blood pressure and improving the heart's energy metabolism is acting as another significant growth-inducing factor. Besides this, the inflating demand for transcutaneous electrical nerve stimulation (TENS), which involves delivering a small electrical current to the nerves to reduce pain and discomfort associated with the ailment, is also creating a positive outlook for the market. Furthermore, the introduction of several enhanced drug delivery systems, including implantable drug delivery devices and targeted drug delivery systems, to improve the effectiveness of anti-anginal drugs is expected to drive the angina market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the angina market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for angina and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the angina market in any manner.

#### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

#### Countries Covered

United States

Germany

France

United Kingdom

Italy

Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario

Historical, current, and future performance of the angina market

Historical, current, and future performance of various therapeutic categories in the market

Sales of various drugs across the angina market

Reimbursement scenario in the market

In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current angina marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview

Mechanism of Action

Regulatory Status

Clinical Trial Results

Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview

Mechanism of Action

Regulatory status

Clinical Trial Results

Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

How has the angina market performed so far and how will it perform in the coming

years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the angina market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the angina market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

### Epidemiology Insights

What is the number of prevalent cases (2018-2034) of angina across the seven major markets?

What is the number of prevalent cases (2018-2034) of angina by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of angina by gender across the seven major markets?

What is the number of prevalent cases (2018-2034) of angina by type across the seven major markets?

How many patients are diagnosed (2018-2034) with angina across the seven major markets?

What is the size of the angina patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of angina?

What will be the growth rate of patients across the seven major markets?

### Angina: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for angina drugs across the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc.

related to the angina market?

What are the key regulatory events related to the angina market?

What is the structure of clinical trial landscape by status related to the angina market?

What is the structure of clinical trial landscape by phase related to the angina market?

What is the structure of clinical trial landscape by route of administration related to the angina market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 ANGINA - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 ANGINA - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 ANGINA - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (2018-2034)
  - 7.2.4 Epidemiology by Gender (2018-2034)
  - 7.2.5 Epidemiology by Type (2018-2034)
  - 7.2.6 Diagnosed Cases (2018-2034)
  - 7.2.7 Patient Pool/Treated Cases (2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (2018-2034)
  - 7.3.4 Epidemiology by Gender (2018-2034)
  - 7.3.5 Epidemiology by Type (2018-2034)
  - 7.3.6 Diagnosed Cases (2018-2034)
  - 7.3.7 Patient Pool/Treated Cases (2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (2018-2034)
  - 7.4.4 Epidemiology by Gender (2018-2034)
  - 7.4.5 Epidemiology by Type (2018-2034)
  - 7.4.6 Diagnosed Cases (2018-2034)
  - 7.4.7 Patient Pool/Treated Cases (2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (2018-2034)
  - 7.5.4 Epidemiology by Gender (2018-2034)
  - 7.5.5 Epidemiology by Type (2018-2034)
  - 7.5.6 Diagnosed Cases (2018-2034)
  - 7.5.7 Patient Pool/Treated Cases (2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (2018-2034)
  - 7.6.4 Epidemiology by Gender (2018-2034)
  - 7.6.5 Epidemiology by Type (2018-2034)
  - 7.6.6 Diagnosed Cases (2018-2034)

7.6.7 Patient Pool/Treated Cases (2018-2034)

7.7 Epidemiology Scenario - Italy

7.7.1 Epidemiology Scenario (2018-2023)

7.7.2 Epidemiology Forecast (2024-2034)

7.7.3 Epidemiology by Age (2018-2034)

7.7.4 Epidemiology by Gender (2018-2034)

7.7.5 Epidemiology by Type (2018-2034)

7.7.6 Diagnosed Cases (2018-2034)

7.7.7 Patient Pool/Treated Cases (2018-2034)

7.8 Epidemiology Scenario - Spain

7.8.1 Epidemiology Scenario (2018-2023)

7.8.2 Epidemiology Forecast (2024-2034)

7.8.3 Epidemiology by Age (2018-2034)

7.8.4 Epidemiology by Gender (2018-2034)

7.8.5 Epidemiology by Type (2018-2034)

7.8.6 Diagnosed Cases (2018-2034)

7.8.7 Patient Pool/Treated Cases (2018-2034)

7.9 Epidemiology Scenario - Japan

7.9.1 Epidemiology Scenario (2018-2023)

7.9.2 Epidemiology Forecast (2024-2034)

7.9.3 Epidemiology by Age (2018-2034)

7.9.4 Epidemiology by Gender (2018-2034)

7.9.5 Epidemiology by Type (2018-2034)

7.9.6 Diagnosed Cases (2018-2034)

7.9.7 Patient Pool/Treated Cases (2018-2034)

## **8 ANGINA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

8.1 Guidelines, Management and Treatment

8.2 Treatment Algorithm

## **9 ANGINA - UNMET NEEDS**

## **10 ANGINA - KEY ENDPOINTS OF TREATMENT**

## **11 ANGINA - MARKETED PRODUCTS**

11.1 List of Angina Marketed Drugs Across the Top 7 Markets

11.1.1 Nitrostat (Nitroglycerin sublingual) - Pfizer



- 11.1.1.1 Drug Overview
- 11.1.1.2 Mechanism of Action
- 11.1.1.3 Regulatory Status
- 11.1.1.4 Clinical Trial Results
- 11.1.1.5 Sales Across Major Markets
- 11.1.2 Ranexa (Ranolazine extended release) - Gilead Sciences
  - 11.1.2.1 Drug Overview
  - 11.1.2.2 Mechanism of Action
  - 11.1.2.3 Regulatory Status
  - 11.1.2.4 Clinical Trial Results
  - 11.1.2.5 Sales Across Major Markets
- 11.1.3 Lovenox (Enoxaparin sodium) - Sanofi
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Tiazac (diltiazem hydrochloride) - Forest Laboratories
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Plavix (Clopidogrel) - Sanofi
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.

## **12 ANGINA - PIPELINE DRUGS**

- 12.1 List of Angina Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 IMB1018972 - Imbria Pharmaceuticals
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results

- 12.1.1.4 Safety and Efficacy
- 12.1.1.5 Regulatory Status
- 12.1.2 AdVEGFXC1 - Xylocor Therapeutics
  - 12.1.2.1 Drug Overview
  - 12.1.2.2 Mechanism of Action
  - 12.1.2.3 Clinical Trial Results
  - 12.1.2.4 Safety and Efficacy
  - 12.1.2.5 Regulatory Status
- 12.1.3 AR 36 - Arbor Pharmaceuticals
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status
- 12.1.4 Ninerafaxstat - Imbria Pharmaceuticals
  - 12.1.4.1 Drug Overview
  - 12.1.4.2 Mechanism of Action
  - 12.1.4.3 Clinical Trial Results
  - 12.1.4.4 Safety and Efficacy
  - 12.1.4.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.

### **13. ANGINA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

### **14. ANGINA – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

### **15 ANGINA - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Angina - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)

- 15.2.2 Angina - Market Size by Therapies
  - 15.2.2.1 Market Size by Therapies (2018-2023)
  - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Angina - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Angina - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Angina - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany
  - 15.4.1 Angina - Market Size
    - 15.4.1.1 Market Size (2018-2023)
    - 15.4.1.2 Market Forecast (2024-2034)
  - 15.4.2 Angina - Market Size by Therapies
    - 15.4.2.1 Market Size by Therapies (2018-2023)
    - 15.4.2.2 Market Forecast by Therapies (2024-2034)
  - 15.4.3 Angina - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Angina - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Angina - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Angina - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Angina - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Angina - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Angina - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Angina - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)

- 15.7.2 Angina - Market Size by Therapies
  - 15.7.2.1 Market Size by Therapies (2018-2023)
  - 15.7.2.2 Market Forecast by Therapies (2024-2034)
- 15.7.3 Angina - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Angina - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Angina - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Angina - Access and Reimbursement Overview
- 15.9 Market Scenario - Japan
  - 15.9.1 Angina - Market Size
    - 15.9.1.1 Market Size (2018-2023)
    - 15.9.1.2 Market Forecast (2024-2034)
  - 15.9.2 Angina - Market Size by Therapies
    - 15.9.2.1 Market Size by Therapies (2018-2023)
    - 15.9.2.2 Market Forecast by Therapies (2024-2034)
  - 15.9.3 Angina - Access and Reimbursement Overview

## **16 ANGINA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 ANGINA MARKET - SWOT ANALYSIS**

- 17.1 Strengths
- 17.2 Weaknesses
- 17.3 Opportunities
- 17.4 Threats

## **18 ANGINA MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Angina Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/ADB31448A30DEN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/ADB31448A30DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

